The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

Explore 6 hopeful Alzheimer’s treatment paths, from innovative therapies to promising research, offering new possibilities ...

Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount ...

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are ...

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

Dismissal of long-standing Alzheimer's research ignores the voices of those who matter most: patients, caregivers and doctors.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

there haven't been hints that removing amyloid far earlier – many years before the first symptoms appear – just might ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...